Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 11/20 | 0.37 |
| ▸ | CACNA1G | O43497 | 4/20 | 0.32 |
| ▸ | CACNA1C | Q13936 | 5/20 | 0.32 |
| ▸ | CACNA1B | Q00975 | 5/20 | 0.31 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.31 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18761555 | 0.83 | CACNA1H (0.36) | CACNA1HCACNA1GCACNA1CCACNA1B | |
| SCHEMBL17437508 | 0.83 | CACNA1H (0.51) | CACNA1HCACNA1GCACNA1CCACNA1B | |
| SCHEMBL18761631 | 0.79 | HRH4 (0.31) | — | |
| SCHEMBL15844295 | 0.77 | CACNA1H (0.44) | CACNA1HCACNA1GCACNA1CCACNA1BADRB1 | |
| Hydrochloric Acid SCHEMBL12495599 | 0.77 | CACNA1H (0.44) | CACNA1HCACNA1GCACNA1CCACNA1BADRB1 | |
| SCHEMBL15843964 | 0.76 | CACNA1H (0.39) | CACNA1HCACNA1GCACNA1CCACNA1BADRB1 | |
| SCHEMBL18761604 | 0.74 | CACNA1H (0.38) | CACNA1HCACNA1GCACNA1CCACNA1B | |
| SCHEMBL10284436 | 0.73 | CACNA1H (0.40) | CACNA1HCACNA1GCACNA1CCACNA1B | |
| SCHEMBL18761567 | 0.73 | CACNA1H (0.52) | CACNA1HCACNA1GCACNA1CCACNA1B | |
| SCHEMBL15843992 | 0.71 | CACNA1H (0.44) | CACNA1HCACNA1GCACNA1CCACNA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10208023-B2 | Heterocyclic inhibitors of the sodium channel | DeGiacomo, Mark G. (US) | 2019-02-19 | — | — | US | disclosed |
| US-20170107203-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | EPIRUS BIOPHARMACEUTICALS, INC. (US) | 2017-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10208023-B2 | Heterocyclic inhibitors of the sodium channel | SCN1B, TRPV1, SCN1A | CACNA1H 32/4885CACNA1G 13/4885CACNA1C 14/4885 |
| US-20170107203-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | SCN1B, SCN1A, CACNA1S | CACNA1H 20/4885CACNA1G 7/4885CACNA1C 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.